Vitamin D deficiency
Conditions
Interventions
25(OH)D < 10 ng/mL and daily oral supplementation of vitamin D2 group:Daily oral supplementation of 5000 units vitamin D2
25(OH)D < 10 ng/mL and oral supplementation of vitamin D2 every other day group:Oral supplementation of 5000 units vitamin D2 every other day
25(OH)D<10 ng/mL and daily oral supplementation of vitamin D3 group:Daily oral supplementation of 800 units vitamin D3
25(OH)D = 10 ng/mL and daily oral supplementation of vitamin D2 group:Daily oral supplementation of 5000 units vitamin D2 group
25(OH)D = 10 ng/mL and oral supplementation of vitamin D2 every other day group:Oral supplementation of 5000 units vitamin D2 every other day
25(OH)D = 10 ng/mL and daily oral supplementation of vitamin D3 group:Daily oral supplementation of 800 units vitamin D3
Sponsors
The Second Xiangya Hospital, Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. 25-hydroxyvitamin D level < 20 ng/ml; 2. Aged between 18 and 60 years; 3. No liver or kidney dysfunction or other serious diseases; 4. No long-term travel planned in the tropical region within 12 months after the trial started; 5. Willingness to participate in this study and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Vitamin D supplements in the last 6 months; 2. A history of any drugs that could affect vitamin D metabolism in the last 6 months; 3. Reluctance to participate in research; 4. A history of cognitive impairment or somatic dysfunction affecting completion of study; 5. A history of Hypercalcemia, vitamin D overdose or poisoning, renal insufficiency, chronic diarrhea, hypoproteinemia, or other conditions affecting vitamin D metabolism.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 25-hydroxyvitamin D3;25-hydroxyvitamin D2;25-hydroxyvitamin D; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum calcium;Serum creatinine;24-hour urine calcium;24-hour urine creatinine;Liver function;Serum osteocalcin;Serum intact parathyroid hormone;Serum ß-C-terminaltelopeptide typeIcollagen;Serum N-terminal propeptide of type I procollagen;Body composition;Grip strength;Vitamin D binding protein; | — |
Countries
China
Contacts
Public ContactZhongjian Xie
The Second Xiangya Hospital, Central South University
Outcome results
None listed